It is therefore not surprising that this is the clinical feature most targeted in NASH drug discovery, but it is also the hardest to model pre-clinically, relying on rodent models such as the use of CCL4 which is known to be poorly predictive of human disease16,54. Here, CCL4 is linked to metabolic dysfunction-associated steatohepatitis.